Revision 2
Cell Signaling Technology

Orders: 877-616-CELL (2355) [email protected]

Support: 877-678-TECH (8324)

Web: [email protected] cellsignal.com

3 Trask LaneDanversMassachusetts01923USA
For Research Use Only. Not for Use in Diagnostic Procedures.
REACTIVITY:

H

SENSITIVITY:

Endogenous

MW (kDa):

Source/Isotype:

Human IgG1 kappa

UniProt ID:

#Q9NZQ7

Entrez-Gene Id:

29126

Product Information

Product Usage Information

This product is intended for research use only (RUO). Optimal dilutions/concentrations should be determined by the end user.

Formulation

Supplied in 1X PBS, BSA and Azide Free.

Storage

Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance.

Specificity / Sensitivity

PD-L1 (Atezolizumab Biosimilar) Human mAb was confirmed to bind to its intended target protein PD-L1 using flow cytometry and bio-layer interferometry.

Species Reactivity:

Human

Source / Purification

PD-L1 (Atezolizumab Biosimilar) Human mAb is produced at Cell Signaling Technology. Atezolizumab is an antibody that is directed against the extracellular region of human PD-L1.

Product Description

PD-L1 (Atezolizumab Biosimilar) Human mAb is a biosimlar antibody for Atezolizumab. Atezolizumab is a human monoclonal antibody directed against PD-L1 that is designed to function as an immune checkpoint inhibitor by disrupting the interaction between PD-L1 and PD-1.
Endotoxin <0.1 EU/μg of antibody

Background

Programmed cell death 1 ligand 1 (PD-L1, B7-H1, CD274) is a member of the B7 family of cell surface ligands that regulate T cell activation and immune responses. The PD-L1 ligand binds the PD-1 transmembrane receptor and inhibits T cell activation. PD-L1 was discovered following a search for novel B7 protein homologs and was later shown to be expressed by antigen presenting cells, activated T cells, and tissues including placenta, heart, and lung (1-3). Similar in structure to related B7 family members, PD-L1 protein contains extracellular IgV and IgC domains and a short, cytoplasmic region. Research studies demonstrate that PD-L1 is expressed in several tumor types, including melanoma, ovary, colon, lung, breast, and renal cell carcinomas (4-6). Expression of PD-L1 in cancer is associated with tumor-infiltrating lymphocytes, which mediate PD-L1 expression through the release of interferon gamma (7). Additional research links PD-L1 expression to cancers associated with viral infections (8,9).

  1. Dong, H. et al. (1999) Nat Med 5, 1365-9.
  2. Freeman, G.J. et al. (2000) J Exp Med 192, 1027-34.
  3. Liang, S.C. et al. (2003) Eur J Immunol 33, 2706-16.
  4. Dong, H. et al. (2002) Nat Med 8, 793-800.
  5. Thompson, R.H. et al. (2006) Cancer Res 66, 3381-5.
  6. Pardoll, D.M. (2012) Nat Rev Cancer 12, 252-64.
  7. Taube, J.M. et al. (2012) Sci Transl Med 4, 127ra37.
  8. Lyford-Pike, S. et al. (2013) Cancer Res 73, 1733-41.
  9. Chen, B.J. et al. (2013) Clin Cancer Res 19, 3462-73.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Cross-Reactivity Key

H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

限制使用

除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。

专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专

Revision 2
#33052

PD-L1 (Atezolizumab Biosimilar) Human mAb

PD-L1 (Atezolizumab Biosimilar) Human mAb: Image 1 Expand Image
Binding kinetics of PD-L1 (Atezolizumab Biosimilar) Human mAb to recombinant PD-L1 were measured using bio-layer interferometry (BLI) on the Octet RED96 (Sartorius). Antibodies were immobilized to ProA biosensors (Sartorius), which were then dipped into wells containing a 2-fold dilution series of recombinant PD-L1. Concentrations tested ranged from 1,000 nM to 15.6 nM. Global curve-fitting was performed using a 1:1 binding model; only the concentrations that passed that fitting are shown.
PD-L1 (Atezolizumab Biosimilar) Human mAb: Image 2 Expand Image
Flow cytometric analysis of PC-3 cells (blue, negative) and Sup-M2 cells (green, positive) using PD-L1 (Atezolizumab Biosimilar) Human mAb (solid lines) or concentration-matched Human IgG Isotype Control (dashed lines). Anti-human IgG (H+L) (Alexa Fluor® 488 Conjugate) was used as a secondary antibody.